Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

* Age of 18-70 years
* Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer
* Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy.
* Patients with measurable lesions
* Eatern Cooperative Oncolgy Group status 0 to 2.
* Life expectancy \>/= 5 months
* Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by

  1. Absolute neutrophil count \>/= 1.5 x 10\^9/L, Platelet count \>/= 100 x 10\^9/L
  2. Total bilirubin \</= upper limit of normal
  3. Aspartate Aminotransferase and/or Alanine Aminotransferase \</= 2 x upeer limit of normal
  4. creatinine \</= 1.5 x upeer limit of normal
* Patients who have signed the informed consent form.

Exclusion Criteria:

* Female volunteers admitted to the study must be using a reliable means of contraception
* Received radiation therapy within 6 weeks before randomization
* Known brain or spinal cord metastases
* Have acute infection
* Have active infection or serious concomitant systemic disorder incompatible with the study
* Presence or history of malignancy other than Non-Small Cell Lung Cancer
* Have severe neurologic or psychological disorder
* Patients who have to receive other chemo-radiotherapy or immunotherapy
* Patients who have received chemotherapy within the previous 30 days
* Patients who are candidates for combined modality treatment.
* Patients who have participated in a clinical study within the previous 30 days